IBOV 172,236.05 ▲ 2.22% IPC MEX 72,104.80 ▲ 1.00% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.04% USD/MXN18.50▼ 0.17% USD/CLP966.96▼ 0.99% USD/COP3,269▲ 0.88% USD/PEN3.41▼ 1.07% USD/ARS1,545▼ 0.02% USD/UYU40.45▲ 0.35% USD/PYG6,450▲ 1.45% USD/BOB11.74▼ 0.59% USD/DOP60.46▲ 2.41% USD/CRC446.56▼ 0.38% USD/GTQ7.64▼ 0.05% USD/HNL26.89▲ 0.02% USD/NIO36.62▲ 2.53% USD/VES897.02▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.79▲ 2.42% USD/TTD6.72▼ 0.03% EUR/BRL6.18▲ 0.80% BRENT 91.55 ▼ 1.10% WTI 85.83 ▼ 1.17% IRON ORE 161.91 — — COPPER 6.37 ▲ 0.62% GOLD 4,130 ▲ 0.37% SILVER 53.41 ▲ 1.60% SOY 1,191 ▲ 0.76% CORN 441.00 ▲ 0.40% WHEAT 589.00 ▲ 0.17% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81% IBOV 172,236.05 ▲ 2.22% IPC MEX 72,104.80 ▲ 1.00% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.04% USD/MXN 18.50 ▼ 0.16% USD/CLP 966.96 ▼ 0.99% USD/COP 3,269 ▲ 0.88% USD/PEN 3.41 ▼ 1.07% USD/ARS 1,545 ▼ 0.02% USD/UYU 40.45 ▲ 0.35% USD/PYG 6,450 ▲ 1.45% USD/BOB 11.74 ▼ 0.59% USD/DOP 60.46 ▲ 2.41% USD/CRC 446.56 ▼ 0.38% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.89 ▲ 0.02% USD/NIO 36.62 ▲ 2.53% USD/VES 897.02 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.79 ▲ 2.42% USD/TTD 6.72 ▲ 2.10% EUR/BRL 6.18 ▲ 0.80% BRENT 91.55 ▼ 1.10% WTI 85.83 ▼ 1.17% IRON ORE 161.91 — — COPPER 6.37 ▲ 0.62% GOLD 4,130 ▲ 0.37% SILVER 53.41 ▲ 1.60% SOY 1,191 ▲ 0.76% CORN 441.00 ▲ 0.40% WHEAT 589.00 ▲ 0.17% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81%
since 2009
Tuesday, November 10, 2026

Covid-19 Brazil

Brazil’s health regulator authorizes Butantan to conduct human trials for anti-Covid serum

By · · 2 min read

RIO DE JANEIRO, BRAZIL – The Brazilian Health Regulatory Agency (ANVISA) on Tuesday, May 25, authorized the start of trials of the anti-Sars-CoV-2 serum, developed by the Butantan Institute, in São Paulo.

With the decision, the Butantan Institute may begin to test the serum on trial volunteers. This will be the first time that the serum will be tested in humans.

Brazil’s health regulator authorizes Butantan to conduct human trials for anti-Covid serum
The serum is a concentrate of antibodies against the novel coronavirus and can be administered as soon as patients display clinical symptoms of the disease
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

On March 24, the agency had approved the research, but conditioned to the signing of a term of commitment that provided for the delivery of additional data, which were not available at that time.

Yesterday’s authorization was granted after Butantan supplied the agency with the new clinical protocol with the required adjustments so human trials could be initiated.

The serum is a concentrate of antibodies against the novel coronavirus and can be administered as soon as patients display clinical symptoms of the disease. In March, Butantan had announced that the clinical trial would include transplant patients from the Hospital do Rim (Kidney Hospital) and patients with comorbidities from the Clínicas Hospital, both in the city of São Paulo.

According to ANVISA, the agency conducted the full assessment of the trial proposal, with no involvement of other foreign agencies, since the serum’s initial clinical trial phases will be conducted only in Brazil. “As this is the first time that the Butantan serum will be tested in people, this demanded a careful assessment of the product’s technical and safety aspects,” it pointed out in an official statement. So far, the serum has only been tested on animals.

Also yesterday, ANVISA received a new request for importation from India of the Covaxin vaccine against Covid-19. The request is to import 20 million doses and was submitted by the Ministry of Health on Monday, May 24.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.